Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s stock price traded up 1.6% during trading on Thursday . The company traded as high as $10.99 and last traded at $10.89. 101 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 5,519 shares. The stock had previously closed at $10.72.
Drugs Made in America Acquisition Stock Performance
The business’s 50 day simple moving average is $10.81 and its two-hundred day simple moving average is $10.63.
About Drugs Made in America Acquisition
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Further Reading
- Five stocks we like better than Drugs Made in America Acquisition
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
